Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR01275
|
|||||
| Drug Name |
Entacapone
|
|||||
| Synonyms |
(2E)-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)-N,N-diethylprop-2-enamide; (E)-2-Cyano-3-(3,4-dihydroxy-5-nitrophenyl)-N,N-diethyl-2-propenamide; (E)-2-cyano-3-(3,4-dihydroxy-5-nitro-phenyl)-N,N-diethyl-prop-2-enamide; (E)-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)-N,N-diethylprop-2-enamide; (E)-alpha-Cyano-N,N-diethyl-3,4-dihydroxy-5-nitrocinnamamide; 2-Cyano-N,N-diethyl-3-(3,4-dihydroxy-5-nitrophenyl)propenamide; COM-998; Comtan; Comtan (TN); Comtess; Entacapona; Entacapona [INN-Spanish]; Entacapone (JAN/USAN/INN); Entacapone [USAN:INN]; Entacaponum; Entacaponum [INN-Latin]; KB475572; N,N-diethyl-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl) acrylamide; Novartis brand of entacapone; OR 611; OR-611; Orion brand of entacapone; Stalevo (TN)
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Parkinson's Disease [ICD11:8A00.0] | Approved | [1] | |||
| Therapeutic Class |
Antiparkinson Agents
|
|||||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C14H15N3O5
|
|||||
| Canonical SMILES |
CCN(CC)C(=O)C(=CC1=CC(=C(C(=C1)O)O)[N+](=O)[O-])C#N
|
|||||
| InChI |
InChI=1S/C14H15N3O5/c1-3-16(4-2)14(20)10(8-15)5-9-6-11(17(21)22)13(19)12(18)7-9/h5-7,18-19H,3-4H2,1-2H3/b10-5+
|
|||||
| InChIKey |
JRURYQJSLYLRLN-BJMVGYQFSA-N
|
|||||
| CAS Number |
CAS 130929-57-6
|
|||||
| Pharmaceutical Properties | Molecular Weight | 305.29 | Topological Polar Surface Area | 130 | ||
| Heavy Atom Count | 22 | Rotatable Bond Count | 4 | |||
| Hydrogen Bond Donor Count | 2 | Hydrogen Bond Acceptor Count | 6 | |||
| XLogP |
2.1
|
|||||
| PubChem CID | ||||||
| PubChem SID |
10145
,7847846
,7979169
,8616509
,11528716
,12014660
,14776335
,26757974
,39290001
,46508734
,49658624
,50064207
,50214283
,53790856
,57358005
,92308972
,92719407
,93166184
,103248957
,104004044
,113854525
,119504915
,121682934
,124893160
,126530712
,126592033
,126620827
,126653084
,126666453
,131297374
,134337899
,135017133
,135032923
,137001453
,141610450
,144115941
,144205737
,152104428
,160963840
,163620784
,163686109
,164814929
,164840953
,170464850
,172917348
,175268297
,175610943
,176484081
,177748942
,178103260
|
|||||
| ChEBI ID |
ChEBI:4798
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | BCRP | Transporter Info | Breast cancer resistance protein | Substrate | [2] | |
| OATP1B1 | Transporter Info | Organic anion transporting polypeptide 1B1 | Substrate | [3] | ||
| References | ||||||
| 1 | Entacapone was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | Elucidation of the Impact of P-glycoprotein and Breast Cancer Resistance Protein on the Brain Distribution of Catechol-O-Methyltransferase Inhibitors. Drug Metab Dispos. 2017 Dec;45(12):1282-1291. | |||||
| 3 | Organic Anion Transporter 2-Mediated Hepatic Uptake Contributes to the Clearance of High-Permeability-Low-Molecular-Weight Acid and Zwitterion Drugs: Evaluation Using 25 Drugs. J Pharmacol Exp Ther. 2018 Nov;367(2):322-334. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Li and Dr. Fu.